4basebio (LON:4BB) Stock Price Down 0.9% – Here’s Why

4basebio PLC (LON:4BB) dropped 0.9% during trading on Wednesday . The company traded as low as GBX 584.40 and last traded at GBX 584.40. Approximately 1,278 shares were traded during trading, a decline of 8% from the average daily volume of 1,393 shares. The stock had previously closed at GBX 590.

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada reiterated an “outperform” rating and issued a GBX 1,600 price target on shares of 4basebio in a research report on Thursday, October 2nd. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of GBX 1,600.

4basebio Stock Performance

The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The business has a 50 day moving average price of GBX 647.54 and a two-hundred day moving average price of GBX 781.85. The stock has a market cap of £90.49 million, a P/E ratio of -5.90 and a beta of 1.09.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.